Pan, Yan <br/><br/>
Enoxaparin sensitizes human non-small-cell lung carcinomas to gefitinib by inhibiting DOCK1 expression, vimentin phosphorylation, and Akt activation.  [electronic resource] 

 -  Molecular pharmacology  2015 
 - 378-90 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1521-0111 
<br/><br/><label>Standard No.: </label>10.1124/mol.114.094425  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Antineoplastic Combined Chemotherapy Protocols--administration & dosage<br/>Carcinoma, Non-Small-Cell Lung--drug therapy<br/>Cell Line, Tumor<br/>Enoxaparin--administration & dosage<br/>Gefitinib<br/>Gene Expression Regulation, Neoplastic<br/>Humans<br/>Lung Neoplasms--drug therapy<br/>Mice<br/>Mice, Inbred BALB C<br/>Mice, Nude<br/>Phosphorylation--drug effects<br/>Proto-Oncogene Proteins c-akt--antagonists & inhibitors<br/>Quinazolines--administration & dosage<br/>Vimentin--antagonists & inhibitors<br/>Xenograft Model Antitumor Assays--methods<br/>rac GTP-Binding Proteins--antagonists & inhibitors